Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effects of Vascular Disease Risk Factors on Brain ATP in People with Multiple Sclerosis—A 3-year Longitudinal Study
Multiple Sclerosis
P11 - Poster Session 11 (5:30 PM-6:30 PM)
6-010
VDRF, such as hyperlipidemia, hypertension, obesity, diabetes, and heart disease, appear to significantly increase the risk of disability progression in pwMS, however the underlying mechanisms are not understood. We previously published baseline data that VDRF+ pwMS have significantly reduced brain ATP compared with VDRF- pwMS.

Describe the effects of VDRF (vascular disease risk factors) on brain phosphate metabolism and disease progression in pwMS (people with multiple sclerosis) over time.

This is a 3-year prospective, observational, single-site, study with two arms (pwMS with and without VDRF). We collected 7T MRI and 31P MRS (magnetic resonance spectroscopy) data at baseline (n=51), 12 (n=42), 24 (n=35), 36 (n=33) months, and clinical data every 6 months. Outcome measures include changes in: 1) cerebral ATP, 2) brain parenchymal volume, and 3) clinical outcomes. The ATP data was analyzed using a mixed methods repeated measures model using age, sex, regional brain volume, baseline ATP, and VDRF status for each subject over 4 time points as predictors.
At baseline, mean age/ sex was 56.4 years/ 82.1% female (N=28) for VDRF+, and 52.4 years/ 56.5% female (N=23) for VDRF-. Preliminary findings suggest that increased age was associated with decreased ATP levels (p<0.01). After controlling for baseline differences, demographic variables, and brain tissue compartments, ATP levels did not change or differ between the two VDRF groups during the 36 month period.
This is the first longitudinal prospective study to assess brain metabolism in pwMS with and without VDRF. With increasing age, we observed decreased ATP levels. However, the presence of VDRF did not appear to influence ATP levels in this small cohort over the 36 month study period.
Authors/Disclosures
Helen Wu, MD, PhD (OHSU)
PRESENTER
Dr. Wu has nothing to disclose.
Jacob B. Perlman, MD (Oregon Health and Science University) Dr. Perlman has nothing to disclose.
Alex Stevens (OHSU) No disclosure on file
Michael A. Lane, MD (OHSU) Dr. Lane has nothing to disclose.
Allison Fryman No disclosure on file
Frank Bittner, DO Dr. Bittner has nothing to disclose.
William Rooney, PhD (Oregon Health & Science University) Dr. Rooney has nothing to disclose.
Manoj K. Sammi, PhD (Oregon Health & Science Univ) Dr. Sammi has received research support from Race to Erase MS. Dr. Sammi has received research support from Myelin Repair Foundation. Dr. Sammi has received research support from Revalesio. Dr. Sammi has received research support from Paul G. Allen Family Foundation. Dr. Sammi has received research support from Conrad F Hilton Foundation Innovation Fund. Dr. Sammi has received research support from NIH/NIDDK.
Vijayshree Yadav, MD, FAAN (OHSU) Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb Foundation. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD-Serono . The institution of Dr. Yadav has received research support from Department of Veterans Affairs. Dr. Yadav has received research support from NIH. Dr. Yadav has received research support from PCORI. Dr. Yadav has received research support from NMSS. The institution of Dr. Yadav has received research support from Department of Veterans Affairs. The institution of Dr. Yadav has received research support from Tykeson Family Foundation Endowed Professorship.